Katherine M. Moxley

Katherine M. Moxley

Obstetrics and Gynecology
12697 E 51st St
Tulsa, OK 74146

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 44 publications

Feasibility IB trial of paclitaxel/carboplatin + Galunisertib. (a small molecule inhibitor of the kinase domain of type 1 TGF-B receptor) in patients with newly diagnosed, persistent or recurrent carcinosarcoma of the uterus or ovary.

Feasibility IB trial of paclitaxel/carboplatin + Galunisertib. (a small molecule inhibitor of the kinase domain of type 1 TGF-B receptor) in patients with newly diagnosed, persistent or recurrent carcinosarcoma of the uterus or ovary.

Journal: Gynecologic oncology
Published: July 11, 2025

Corrigendum to "Targeting doublecortin-like kinase 1 reveals a novel strategy to circumvent chemoresistance and metastasis in ovarian cancer" [Cancer Lett. 2023 Dec 1;578:216437].

Corrigendum to "Targeting doublecortin-like kinase 1 reveals a novel strategy to circumvent chemoresistance and metastasis in ovarian cancer" [Cancer Lett. 2023 Dec 1;578:216437].

Journal: Cancer letters
Published: July 03, 2025

A mobile health app for real-time symptom monitoring in patients with cancer during COVID-19: feasibility, acceptability, and utility.

A mobile health app for real-time symptom monitoring in patients with cancer during COVID-19: feasibility, acceptability, and utility.

Journal: BMC cancer
Published: January 16, 2025

ATR inhibition increases reliance on PARP-mediated DNA repair revealing an improved therapeutic strategy for cervical cancer.

ATR inhibition increases reliance on PARP-mediated DNA repair revealing an improved therapeutic strategy for cervical cancer.

Journal: Gynecologic oncology
Published: May 16, 2024

Oklahoma nitrone-007 is an effective anticancer therapeutic agent targeting inflammatory and immune metabolism pathways in endometrial cancer.

Oklahoma nitrone-007 is an effective anticancer therapeutic agent targeting inflammatory and immune metabolism pathways in endometrial cancer.

Journal: The Journal of pharmacology and experimental therapeutics
Published: March 13, 2024

Targeting doublecortin-like kinase 1 reveals a novel strategy to circumvent chemoresistance and metastasis in ovarian cancer.

Targeting doublecortin-like kinase 1 reveals a novel strategy to circumvent chemoresistance and metastasis in ovarian cancer.

Journal: Cancer letters
Published: August 08, 2023

Improving Risk Assessment for Metastatic Disease in Endometrioid Endometrial Cancer Patients Using Molecular and Clinical Features: An NRG Oncology/Gynecologic Oncology Group Study.

Improving Risk Assessment for Metastatic Disease in Endometrioid Endometrial Cancer Patients Using Molecular and Clinical Features: An NRG Oncology/Gynecologic Oncology Group Study.

Journal: Cancers
Published: June 17, 2022

TP53 Sequencing and p53 Immunohistochemistry Predict Outcomes When Bevacizumab Is Added to Frontline Chemotherapy in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study.

TP53 Sequencing and p53 Immunohistochemistry Predict Outcomes When Bevacizumab Is Added to Frontline Chemotherapy in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 06, 2022

Olaparib With or Without Cediranib Versus Platinum-Based Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer (NRG-GY004): A Randomized, Open-Label, Phase III Trial.

Olaparib With or Without Cediranib Versus Platinum-Based Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer (NRG-GY004): A Randomized, Open-Label, Phase III Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: March 15, 2022

Sera Protein Signatures of Endometrial Cancer Lymph Node Metastases.

Sera Protein Signatures of Endometrial Cancer Lymph Node Metastases.

Journal: International journal of molecular sciences
Published: February 25, 2022

A phase II trial of bevacizumab and rucaparib in recurrent carcinoma of the cervix or endometrium.

A phase II trial of bevacizumab and rucaparib in recurrent carcinoma of the cervix or endometrium.

Journal: Gynecologic oncology
Published: December 09, 2021

Patient-Derived Xenografts of High-Grade Serous Ovarian Cancer Subtype as a Powerful Tool in Pre-Clinical Research.

Patient-Derived Xenografts of High-Grade Serous Ovarian Cancer Subtype as a Powerful Tool in Pre-Clinical Research.

Journal: Cancers
Published: November 12, 2021
Showing 1-12 of 44

Last Updated: 09/26/2026